# TRK-950

Source: https://onco.cc/drugs/trk-950/  
OnCo record `trk-950` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TRK-950 is an experimental investigational agent whose form is not stated in the registry from Toray Industries in phase 2 trials for gastric & gastro-oesophageal junction cancer and melanoma, aimed at NTRK.

## Summary

TRK-950 is an investigational agent whose form is not stated in the registry developed by Toray Industries. Its target is NTRK. ClinicalTrials.gov describes the intervention as: 5 mg/kg or 10 mg/kg IV infusion over 60 minutes on Day 1, 8, 15 and 21 of each 28 day cycle. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in gastric & gastro-oesophageal junction cancer and melanoma. The largest, NCT06038578, plans to enrol 146 participants with primary completion was scheduled for 2026-06-30 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: monoclonal antibody (per the sponsor's pipeline page; form not stated in the registry record)
- Mechanism: Investigational agent whose form is not stated in the registry directed at NTRK, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of TRK-950: https://clinicaltrials.gov/search?intr=TRK-950
- Sponsor page: https://www.toray.com

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Melanoma](https://onco.cc/cancers/melanoma/)
- targets: [NTRK](https://onco.cc/targets/ntrk/)
- companies: [Toray Industries](https://onco.cc/companies/toray-industries/)
- trials: [A Study of TRK-950 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05423262/), [A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer](https://onco.cc/trials/nct06038578/)

---
JSON: https://onco.cc/api/v1/entities/trk-950.json